𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib

✍ Scribed by Edward J. Kim; Mark M. Zalupski

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
88 KB
Volume
104
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Progression on first‐line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib‐resistant GIST include agents that target KIT/PDGFR with greater potency or possess broader kinase inhibition profiles including VEGFR. To circumvent secondary mutations in KIT/PDGFR, inhibition of the downstream signaling in PI3K/Akt/mTOR pathway and enhanced degradation of KIT/PDGFR are also under investigation. J. Surg. Oncol. 2011; 104:901–906. Β© 2011 Wiley Periodicals, Inc.

πŸ“œ SIMILAR VOLUMES

Imatinib as adjuvant therapy for gastroi
Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review
✍ Munira Essat; Katy Cooper πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 266 KB πŸ‘ 1 views

## Abstract The high risk of recurrence in resected gastrointestinal stromal tumor (GIST) highlights the need for effective adjuvant treatment. This review evaluates the clinical efficacy and safety of imatinib for adjuvant treatment of localized KIT (CD117)‐positive resected GIST. Relevant studies

Surgical options for localized and advan
Surgical options for localized and advanced gastrointestinal stromal tumors
✍ Timothy L. Frankel; Alfred E. Chang; Sandra L. Wong πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 236 KB

## Abstract The development of imitinab has led to a revolution in the management of gastrointestinal stromal tumors (GIST), but surgical resection remains the cornerstone of treatment for patients with localized disease. The principles to surgical treatment of GIST include careful handling of tiss

Adjuvant and neoadjuvant imatinib therap
Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors
✍ Burton L. Eisenberg; Jonathan C. Trent πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 212 KB

## Abstract Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has off